Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 3 Colorectal Neoplasms 2 Solid Cancer 1 Recurrence 1 Neoplasms 1 Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 1 Hepatic Veno-Occlusive Disease 1 Disease 1 Chemical and Drug Induced Liver Injury 1 Breast Neoplasms 1 Agnosia 1 Adenoma 1

Interventions

pembrolizumab 2 atezolizumab 2 trastuzumab deruxtecan 1 toripalimab 1 pertuzumab 1 fludarabine 1 durvalumab 1 cabazitaxel 1 XRP6258 1 Trastuzumab 1 S-Adenosylmethionine 1 Ramucirumab 1 Paclitaxel 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Irinotecan 1 Fluorouracil 1 Etoposide 1 Cyclophosphamide 1 Cetuximab 1 Carboplatin 1 Capecitabine 1 Bronchoscopes 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Cancer × S-Adenosylmethionine × Clear all

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡